SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

34

PRAGUE–(BUSINESS WIRE)–SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumors. The first patient was treated with SO-C101 at the Institute Gustave Roussy (France). The SC103 clinical trial will also enrol patients in the Vall d’Hebron…

 

http://www.businesswire.com/news/home/20190711005058/en/SOTIO-initiates-first-in-human-clinical-trial-IL-15-superagonist/